Literature DB >> 15531482

Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas.

Agnès Rouxel1, Gilles Hejblum, Marie-Odile Bernier, Pierre-Yves Boëlle, Fabrice Ménégaux, George Mansour, Catherine Hoang, André Aurengo, Laurence Leenhardt.   

Abstract

To estimate survival of patients with loco-regional recurrences (LRRs) of differentiated thyroid carcinomas (DTCs) and to identify factors associated with survival after LRRs, we analyzed retrospective data of the 172 patients treated and followed up in our institution from 1958 to 2000 who had developed LRRs (6% of DTC patients). Ultrasound, when used, picked up 95% of the recurrences. Survival was estimated with the method of Kaplan-Meier, and associated prognostic features were studied in univariate and multivariate Cox model-based analyses. Cumulated survival rates 10 yr after LRRs were 49.1, 89.3, and 32.1% for all patients, patients aged less than 45 yr, and older patients, respectively. Multivariate analysis identified three features related to initial tumor (age >/= 45 yr, follicular histology, presence of thyroid capsular effraction), the absence of radioiodine ablation of thyroid remnants after initial surgery (10% of patients did not receive radioiodine), the presence of distant metastases before LRR diagnosis, and two features related to the LRRs (no radioiodine uptake and thyroid bed location) as significantly associated with a reduced survival. Our results underline the seriousness of LRRs of DTCs and could be used to identify patients who should benefit from a closer follow-up and especially reactive therapeutic intervention.

Entities:  

Mesh:

Year:  2004        PMID: 15531482     DOI: 10.1210/jc.2003-032004

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  A novel definition of extrathyroidal invasion for patients with papillary thyroid carcinoma for predicting prognosis.

Authors:  Muneki Hotomi; Iwao Sugitani; Kazuhisa Toda; Kazuyoshi Kawabata; Yoshihide Fujimoto
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

2.  2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer.

Authors:  L Leenhardt; M F Erdogan; L Hegedus; S J Mandel; R Paschke; T Rago; G Russ
Journal:  Eur Thyroid J       Date:  2013-09-05

3.  One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy.

Authors:  Rosália P Padovani; Teresa S Kasamatsu; Claudia C D Nakabashi; Cleber P Camacho; Danielle M Andreoni; Eduardo Z Malouf; Marilia M S Marone; Rui M B Maciel; Rosa Paula M Biscolla
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

4.  Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.

Authors:  Hendra Budiawan; Ali Salavati; Harshad R Kulkarni; Richard P Baum
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

5.  Which thyroid cancer patients need periodic stimulation tests?

Authors:  Paolo Zanotti-Fregonara; Alexandre Khoury; Françoise Duron; Isabelle Keller; Sophie Christin-Maître; Thierry Kiffel; Marie Elisabeth Toubert; Jean-Yves Devaux; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-14       Impact factor: 9.236

6.  The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma.

Authors:  Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Brian P Mullan; Ian D Hay
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

7.  Adequacy of pathology reports of specimens from patients with differentiated thyroid cancer.

Authors:  Ma Luisa Isidro; Gloria Lugo; Olga Fidalgo; Sara García-Arias
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

8.  Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes.

Authors:  Iwao Sugitani; Kazuhisa Toda; Keiko Yamada; Noriko Yamamoto; Motoko Ikenaga; Yoshihide Fujimoto
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

9.  Clinical significance of p53 protein expression in papillary thyroid carcinoma.

Authors:  Naomi Morita; Yoshifumi Ikeda; Hiroshi Takami
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

10.  [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Authors:  Joanna Kłubo-Gwieździńska; Roman Junik
Journal:  Endokrynol Pol       Date:  2008 Mar-Apr       Impact factor: 1.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.